A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

NCT02514668 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

DRUG: Isatuximab

Sponsor

Sanofi